Effects of cyclosporin A and itraconazole on the pharmacokinetics of atorvastatin in rats

Acta Pharmacologica Sinica

Volumn 29, Issue 10, 2008, Pages 1247-1252

  Dong, Jing ^a   Yu, Xue ^a   Wang, Lei ^a   Sun, Ye Bin ^a   Chen, Xi Jing ^a   Wang, Guang Ji ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Atorvastatin; Cyclosporin A; Cytochrome P450 (CYP) 3A4; Itraconazole; P glycoprotein; Pharamcokinetics

Indexed keywords

ATORVASTATIN; CERIVASTATIN; CYCLOSPORIN A; CYTOCHROME P450 3A4; GLYCOPROTEIN P; ITRACONAZOLE; PITAVASTATIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFUNGAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BILIARY EXCRETION; CONTROLLED STUDY; DRUG CROSS REACTIVITY; DRUG METABOLISM; HUMAN; HYPERLIPIDEMIA; MALE; NONHUMAN; RAT; RHABDOMYOLYSIS;

ANIMALS; ANTIFUNGAL AGENTS; BILE; CALIBRATION; CYCLOSPORINE; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAVENOUS; INTUBATION, GASTROINTESTINAL; ITRACONAZOLE; MALE; P-GLYCOPROTEIN; PYRROLES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 53749090602     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1111/j.1745-7254.2008.00858.x     Document Type: Article

References (29)

1. Zager RA. Rhabdomyolysis and myohemoglobinuric acute renal failure. Kidney Int 1996 49 : 314 26.
2. Ohno Y, Hisaka A, Suzuki H. General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs. Clin Pharma-cokinet 2007 46 : 681 96.
3. Gumprecht J, Zychma M, Grzeszczak W, Kuźniewicz R, Burak W, Zywiec J, et al. Simvastatin-induced rhabdomyolysis in a CsA-treated renal transplant recipient. Med Sci Monit 2003 9 : CS89 91.
4. Kantola T, Kivistö KT, Neuvonen PJ. Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharmacol Ther 1998 64 : 58 65.
5. Neuvonen PJ, Kantola T, Kivistö KT. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 1998 63 : 332 41.
6. Neuvonen PJ, Jalava KM. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 1996 60 : 54 61.
7. Lennem PS H, Fager G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Clin Pharmacokinet 1997 32 : 403 25.
8. Smith PF, Eydelloth RS, Grossman SJ, Stubbs RJ, Schwartz MS, Germershausen JI, et al. HMG-CoA reductase inhibitor-induced myopathy in the rat: cyclosporine A interaction and mechanism studies. J Pharmacol Exp Ther 1991 257 : 1225 35.
9. Ishigami M, Kawabata K, Takasaki W, Ikeda T, Komai T, Ito K, et al. Drug interaction between simvastatin and itraconazole in male and female rats. Drug Metab Dispos 2001 29 : 1068 72.
10. Wierzbicki AS. Atorvastatin. Expert Opin Pharmacother 2001 2 : 819 30.
11. Black A.E, Sinz MW, Hayes RN, Woolf TF. Metabolism and excretion studies in mouse after single and multiple oral doses of the-3-Hydroxy-3-Methyl glutaryl-CoA reductase inhibitor atorvastatin. Drug Metab Dispos 1998 26 : 755 63.
12. Kantola T, Krivisto KT, Nenvonen PJ. Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharmacol Ther 1998 64 : 58 65.
13. Wu X, Whitheld LR, Stewart BH. Atorvastatin transport in the Caco-2 cell model: contributions of P-glycoprotein and proton-mono-carboxylic acid co-transporter. Pharm Res 2000 17 : 209 15.
14. Berruet N, Sentenac S, Auchere D, Gimenez F, Farinotti R, Fernandez C. Effect of efavirenz on intestinal p-glycoprotein and hepatic p450 function in rats. J Pharm Pharmaceut Sci 2005 8 : 226 34.
15. Kageyama M, Namiki H, Fukushima H, Ito Y, Shibata N, Takada K. In vivo effects of cyclosporin A and ketoconazole on the pharmacokinetics of representative substrates for P-glycoprotein and cytochrome P450 (CYP) 3A in rats. Biol Pharm Bull 2005 28 : 316 22.
16. Ma L, Dong J, Chen XJ. Development and validation of atorvastatin by LC-ESI-MS and application in bioequivalence research in healthy Chinese volunteers. Chromatographia 2007 65 : 737 41.
17. Tsuji A, Terasaki T, Takabatake Y, Tenda Y, Tamai I, Yamashima T, et al. P-glycoprotein as the drug efflux pump in primary cultured bovine brain capillary endothelial cells. Life Sci 1992 51 : 1427 37.
18. Terao T, Hisanaga E, Sai Y, Tamai I, Tsuji A. Active secretion of drugs from the small intestinal epithelium in rats by P-glycoprotein functioning as an absorption barrier. J Pharm Pharmacol 1996 48 : 1083 9.
19. Lau YY, Okochi H, Huang Y, Benet LZ. Pharmacokinetics of atorvastatin and its hydroxyl metabolites in rats and the effects of concomitant rifampicin single doses: relevance of First-pass effect from hepatic uptake transporters, and intestinal and hepatic metabolism. Drug Metab Dispos 2006 34 : 1175 81.
20. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 2006 80 : 565 81.
21. Saito M, Hirata-Koizumi M, Miyake S, Hasegawa R. Withdrawal of cerivastatin revealed a flaw of post-marketing surveillance system in the United States. Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku 2005 123 : 41 5.
22. Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacody-namic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000 38 : 41 57.
23. Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet 2002 415 : 343 70.
24. Jacobson TA. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Am J Cardiol 2004 94 : 1140 6.
25. Molden E, Asberg A. Metabolic interactions with statins. Tidsskr Nor Laegeforen 2001 121 : 189 93.
26. Igel M, Sudhop T, von Bergmann K. Metabolism and drug interactions of 3-hydroxyl-3-methylglutaryl coenzyme A-reductase inhibitors (statins). Eur J Clin Pharmacol 2001 57 : 357 64.
27. Maltz HC, Balog DL, Cheigh JS. Rhabdomyolysis associated with concomitant use of atorvastatin and cyclosporine. Ann Pharmacother 1999 33 : 1176 9.
28. Hermann M, Asberg A, Christensen H, Holdaas H, Hartmann A, Reu-bsaet JL. Substantially elevated levels of atorvastatin and metabolites in cyclosporine-treated renal transplant recipients. Clin Pharmacol Ther 2004 76 : 388 91.
29. Launay-Vacher V, Izzedine H, Deray G. Statins' dosage in patients with renal failure and cyclosporine drug-drug interactions in transplant recipient patients. Int J Cardiol 2005 101 : 9 17.